Horizon Pharma (HZNP) Misses Q1 EPS by 2c, Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Horizon Pharma plc Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance
May 8, 2017 7:00 AM EDT-- First-Quarter 2017 Net Sales of $220.9 Million; Up 8 Percent --
-- First-Quarter 2017 Net Loss of $90.6 Million; Adjusted EBITDA of $51.9 Million --
-- First-Quarter 2017 Net Sales from Rare Disease Medicines Increased 75 Percent and Represented 65 Percent of Total Company Net Sales --
-- Increased Investment in its Rapidly Growing Orphan Biologic Medicine for Refractory Chronic Gout, KRYSTEXXA® --
-- Raising KRYSTEXXA Peak Annual Net Sales Estimate to More than $400 Million from More than $250 Million ---- Announces Acquisition of River Vision... More
